Featured

CAR NK cells – the newest drivers on the road

The powerful effects of CD19-targeting CAR T cells against blood cancers have been well documented in a high portion of treated patients. However, CAR T cells can induce significant toxicities, and the fact that this treatment must be personalized...

Prebiotic-Induced Anti-tumor Immunity Attenuates Tumor Growth

Li et al. used syngeneic tumor models to show prebiotic (inulin and mucin)-mediated changes in gut microbiota, which correlated with stimulation of antitumor immunity and reduction in tumor growth. In...

A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target

Freeman et al. identified checkpoint signatures expressed by tumor-infiltrating Tregs purified from multiple human cancer types. RNAseq analysis of sorted tumor Tregs revealed a conserved checkpoint s...

Improved anti-tumor efficacy of chimeric antigen receptor T cells that secrete single-domain antibody fragments

Aiming to render the solid tumor microenvironment more permissive to CAR T therapy, Xie et al. engineered CAR T cells to secrete VHH “nanobodies” – single-domain antibody fragments. Secreted anti-CD47...

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

Using syngeneic s.c. mouse models of 8 different tumor types, Sharma et al. showed that bempegaldesleukin, a long-lived IL-2 prodrug biased to bind IL-2Rβγ (over αβγ), enhanced checkpoint blockade- an...

See all for this week

Previous Digests

Bispecific antibody 7370: will AML meet its match?

February 12, 2020

In an effort to address the significant unmet clinical needs in the treatment of acute myeloid leukemia (AML), Yeung and Krishnamoorthy et al. developed a novel bispecific antibody that targets both CD3 on T cells and FLT3 on AML...

The holy grail: pan-cancer-targeting T cells

February 5, 2020

The holy grail of cancer research is finding one treatment that kills all types of cancer in every affected individual. With this lofty goal in mind, Crowther and Dolton et al. explored unconventional T cells and identified a T...

Special delivery! An oncolytic virus encoding IL-7 and IL-12

January 29, 2020

The immune status of the tumor microenvironment (TME) is known to be a key factor influencing the success or failure of cancer immunotherapy. In an effort to improve the immune status of the TME, Nakao et al. tested the...

See More Digests

Everything New In...

Experimental Immunotherapy

Innovative Methods

Cancer Immunobiology

Popular Tags

About ACIR

ACIR's mission is to fast-track Cancer Immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

More About Us

The field of cancer immunotherapy has exploded in recent years, drawing on the creativity and experience of scientists, clinicians, and patient advocates. ACIR does an incredible job of bringing these groups together toward a common goal of eliminating cancer by disseminating important research findings to the community at large.

— James Allison, PhD

Professor and Chair, Department of Immunology; Executive Director, Immunotherapy Platform; Director, Parker Institute for Cancer Immunotherapy; and Vivian L. Smith Distinguished Chair-Immunology at the University of Texas MD Anderson Cancer Center. 2018 Nobel Prize in Physiology or Medicine.

As a researcher bridging the science and clinical translation of the exciting discoveries of cancer immunotherapy, I applaud the efforts of ACIR to help me, my post-docs and students, and my colleagues keep up to date on all the key innovations driving this field. New knowledge continually refines our current thinking and ACIR keeps that new knowledge fresh and at our fingertips.

— Catherine Wu, MD, PhD

Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School; Institute Member, Broad Institute of Harvard and MIT

There is a critical need to provide reliable information to physicians and researchers. Key limitations are the large amount of data that is being published and the multiple clinical trials available. I welcome the efforts by ACIR to make sense out of all this data and provide a reliable source of information for researchers in cancer immunotherapy.

— Antoni Ribas, MD, PhD

Professor of Medicine, Surgery, Molecular and Medical Pharmacology at the University of California (UCLA); Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC); Director of the Parker Institute for Cancer Immunotherapy (PICI) Center at UCLA

The work of ACIR is so beautifully targeted on something that has the potential of being truly useful even in the earliest stages. What a great idea!

— John Petricciani, MD

President of the International Alliance for Biological Standardization (IABS); Former Director of the Center for Biologics at FDA and former Chief Medical Officer of the Biologicals Unit at WHO

Our understanding of the interaction between the immune system and cancer cells, and also the ways to exploit this interaction clinically, is growing faster than ever before. There is no reliable source of information that can help clinicians and researchers in this field stay up-to-date, and by filling this gap, ACIR facilitates the development of effective cancer immunotherapies for an increasing number of patient groups.

— Ton Schumacher, PhD

Deputy Director of the Netherlands Cancer Institute; Professor of Immunotechnology at Leiden University, The Netherlands; Chief Scientific Officer of Kite Pharma EU; SU2C-CRI Immunotherapy Dream Team member

Cancer Immunotherapy is providing patients with novel and durable treatments and the number of available therapies keeps growing. The mission of ACIR is to accelerate the pace by which the field develops through mapping out the research and clinical landscapes and keeping track of key advances in the field. It has my total support!!

— Robert D. Schreiber, PhD

Alumni Endowed Professor of Pathology and Immunology and Professor of Molecular Microbiology at Washington University School of Medicine, MO; Director of the Washington University Center for Human Immunology and Immunotherapy Programs; Associate Director of the Scientific Advisory Board to the CRI

I fully support the important initiative of ACIR. The field of cancer immunotherapy grows at an exciting pace. Staying on top of foundational discoveries in the field, which is conveniently processed on ACIR, is key for coming up with important new hypotheses about immunotherapeutic cancer treatment strategies.

— Glenn Dranoff, MD, PhD

Global Head of Immuno-Oncology, Novartis Institutes of BioMedical Research

I fully endorse the mission of ACIR to provide a weekly synopsis of the scientific literature in cancer immunotherapy. The value of this approach has been clearly demonstrated by a program I have been involved in with the Prize4Life Foundation, which is dedicated to curing ALS. ALS Forum provides ALS research summaries as well as other content related to clinical trials and is widely used by the ALS research community to keep up to date.

— Tom Maniatis, PhD

Chairman of the Department of Biochemistry and Molecular Biophysics at the Columbia University Medical Center (CUMC) in New York, and Director of the University wide Columbia Precision Medicine Initiative (CPMI)

ACIR has identified a great way to meet the critical need of researchers and clinicians everywhere to stay up to date with the literature in the fast moving and life-saving field of cancer immunotherapy. This will be a fine living tribute to your son Matt and has the potential to help many future cancer victims!

— James S. Economou, MD, PhD

Beaumont Professor of Surgery, Microbiology, Immunology and Molecular Genetics, and Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA)

I am pleased to voice my support for the mission of ACIR to keep cancer immunotherapy researchers up to date with the current advancements in the field. Given the magnitude of new information emerging from this field, I particularly appreciate their efforts to both identify and highlight the key advancements each week and to distill the new information to key take-away points that can be easily grasped.

— Nir Hacohen, PhD

Professor of Medicine, Harvard Medical School; Director, MGH Center for Cancer Immunology; Institute Member, Broad Institute of Harvard and MIT

Featured

In the Spotlight...